Present and Future of Parkinson's Disease in Spain: PARKINSON-2030 Delphi Project.
Parkinson’s disease
Spain
diagnosis
economic impact
epidemiology
management
mortality
quality of life
treatment
Journal
Brain sciences
ISSN: 2076-3425
Titre abrégé: Brain Sci
Pays: Switzerland
ID NLM: 101598646
Informations de publication
Date de publication:
31 Jul 2021
31 Jul 2021
Historique:
received:
12
07
2021
revised:
27
07
2021
accepted:
28
07
2021
entrez:
27
8
2021
pubmed:
28
8
2021
medline:
28
8
2021
Statut:
epublish
Résumé
Parkinson's disease (PD) is a chronic progressive and irreversible disease and the second most common neurodegenerative disease worldwide. In Spain, it affects around 120.000-150.000 individuals, and its prevalence is estimated to increase in the future. PD has a great impact on patients' and caregivers' lives and also entails a substantial socioeconomic burden. The aim of the present study was to examine the current situation and the 10-year PD forecast for Spain in order to optimize and design future management strategies. This study was performed using the modified Delphi method to try to obtain a consensus among a panel of movement disorders experts. According to the panel, future PD management will improve diagnostic capacity and follow-up, it will include multidisciplinary teams, and innovative treatments will be developed. The expansion of new technologies and studies on biomarkers will have an impact on future PD management, leading to more accurate diagnoses, prognoses, and individualized therapies. However, the socio-economic impact of the disease will continue to be significant by 2030, especially for patients in advanced stages. This study highlighted the unmet needs in diagnosis and treatment and how crucial it is to establish recommendations for future diagnostic and therapeutic management of PD.
Identifiants
pubmed: 34439646
pii: brainsci11081027
doi: 10.3390/brainsci11081027
pmc: PMC8393421
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Nat Rev Neurosci. 2020 Feb;21(2):103-115
pubmed: 31907406
Mov Disord. 2016 Sep;31(9):1272-82
pubmed: 27125836
Neurologia. 2016 Jul-Aug;31(6):401-13
pubmed: 23816428
Eur J Neurol. 2013 Jan;20(1):16-34
pubmed: 23279440
J Neurol. 2010 Nov;257(Suppl 2):S249-52
pubmed: 21080185
Lancet Neurol. 2018 Nov;17(11):939-953
pubmed: 30287051
Brain Sci. 2021 Feb 13;11(2):
pubmed: 33668408
Eur J Epidemiol. 2011 Jun;26 Suppl 1:S1-58
pubmed: 21626386
Arch Intern Med. 2003 Dec 8-22;163(22):2716-24
pubmed: 14662625
Brain Sci. 2021 Mar 02;11(3):
pubmed: 33801565
Mov Disord. 2014 Nov;29(13):1615-22
pubmed: 24821648
Neurobiol Dis. 2012 Jun;46(3):590-6
pubmed: 22484304
J Parkinsons Dis. 2020;10(3):757-774
pubmed: 32741777
Lancet Neurol. 2021 Mar;20(3):203-212
pubmed: 33609478
Ann Palliat Med. 2020 Feb;9(Suppl 1):S63-S74
pubmed: 32036671
Annu Rev Biomed Eng. 2019 Jun 4;21:111-143
pubmed: 31167102
Parkinsons Dis. 2017;2017:4047392
pubmed: 28239501
Neurology. 2007 Jan 30;68(5):384-6
pubmed: 17082464
Front Neurol. 2020 Jul 08;11:686
pubmed: 32733372
Mov Disord. 2015 Oct;30(12):1591-601
pubmed: 26474316
Lancet Neurol. 2020 Feb;19(2):170-178
pubmed: 31521533
J Parkinsons Dis. 2020;10(1):89-97
pubmed: 31594253
J Neurol Neurosurg Psychiatry. 2009 Aug;80(8):928-30
pubmed: 19608786
Mov Disord. 2012 Feb;27(2):236-41
pubmed: 21954027
Mov Disord. 2008 Oct 15;23(13):1889-96
pubmed: 18709682
Eur J Neurol. 2008 Apr;15 Suppl 1:14-20
pubmed: 18353132
Mov Disord. 2014 Sep;29(10):1273-80
pubmed: 25044402
Lancet. 2009 Jun 13;373(9680):2055-66
pubmed: 19524782